In the article by Muramatsu et al (Muramatsu T, Matsushita K, Yamashita K, Kondo T, Maeda K, Shintani S, Ichimiya S, Ohno M, Sone T, Ikeda N, Watarai M, Murohara T, for the NAGOYA HEART Study Investigators. Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: NAGOYA HEART Study. Hypertension. 2012;59:580–586. doi: 10.1161/HYPERTENSIONAHA.111.184226), which published online ahead of print January 9, 2012, and appeared in the March 2012 issue of the journal, several corrections were needed.
On page 584, Table 3, in the Outcomes column, “Sudden cardiac death” has been changed to read, “Cardiovascular death.” Also, the following information has been added in table legend: “Admission because of heart failure included 4 adjudicated heart failure patients who rejected hospital admission because of personal reasons and received additional medications. Cardiovascular death included fatal stroke and sudden cardiac death.”
On page 585, in the Acknowledgments, the following information has been added: “The affiliation of Mr. Nobuo Shirahashi is Novartis Pharma KK, Tokyo, Japan, and Department of Preventive Medicine and Environmental Health, Osaka City University Medical School, Osaka, Japan.”
The authors apologize for these errors.
These corrections have been made to the current online version of the article, which is available at http://hyper.ahajournals.org/content/59/3/580.full.
- © 2015 American Heart Association, Inc.